Oakview Dermatology

CLIA Laboratory Citation Details

2
Total Citations
5
Total Deficiencyies
3
Unique D-Tags
CMS Certification Number 36D2111882
Address 2405 N Columbus St, Ste 100, Lancaster, OH, 43130
City Lancaster
State OH
Zip Code43130
Phone(614) 908-1339

Citation History (2 surveys)

Survey - October 2, 2024

Survey Type: Standard

Survey Event ID: 0W9N11

Deficiency Tags: D6107 D6107 D5209

Summary:

Summary Statement of Deficiencies D5209 PERSONNEL COMPETENCY ASSESSMENT POLICIES CFR(s): 493.1235 As specified in the personnel requirements in subpart M, the laboratory must establish and follow written policies and procedures to assess employee and, if applicable, consultant competency. This STANDARD is not met as evidenced by: Based on record review and an interview with the Mohs Department Manager (MDM), the laboratory failed to establish and follow written policies and procedures to assess the competency of the Clinical Consultant (CC), Technical Supervisor (TS), General Supervisor (GS), and Testing Personnel (TP) based on the responsibilities of the position and at a frequency determined by the laboratory. This deficient practice had the potential to affect 585 out of 585 patients tested under the subspecialty of Histopathology from 02/14/2023 through 10/02/2024. Findings Include: 1. Review of the laboratory's form CMS-209 Personnel Report (CLIA) found one individual listed as the CC, TS, GS and TP, and a second individual listed as the CC and TP. 2. Review of the policy and procedure manual titled, "Oakview Dermatology Mohs Laboratory" approved via signature and date by the LD on 01/02/2023 found no mention of instructions for the CC, TS, GS, and TP competency assessment. 3. The Inspector requested an approved competency assessment policy and procedure, and 2023 and 2024 assessment documentation for the CC, TS, GS, and TP based on the responsibilities of the position from the MDM. The MDM confirmed the laboratory did not have an approved competency assessment policy and procedure, did not perform a competency assessment for the CC, TS, GS, and TP and was unable to provide the requested information. The interview occurred on 10/02/2024 at 11:50 a. m. D6107 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(15) Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- The laboratory director must specify, in writing, the responsibilities and duties of each consultant and each supervisor, as well as each person engaged in the performance of the preanalytic, analytic, and postanalytic phases of testing, that identifies which examinations and procedures each individual is authorized to perform, whether supervision is required for specimen processing, test performance or result reporting and whether supervisory or director review is required prior to reporting patient test results. This STANDARD is not met as evidenced by: Based on record review and an interview with the Practice Manager (MDM), the Laboratory Director (LD) failed to specify in writing the duties and responsibilities of the Clinical Consultant (CC), Technical Supervisor (TS), General Supervisor (GS), and Testing Personnel (TP) listed on the form CMS-209. This deficient practice had the potential to affect 585 out of 585 patients tested under the subspecialties of Histopathology from 02/14/2023 through 10/02/2024. Findings include: 1. Review of the laboratory's form CMS-209 Personnel Report (CLIA) found one individual listed as the CC, TS, GS and TP, and a second individual listed as the CC and TP. 2. Review of the policy and procedure manual titled, "Oakview Dermatology Mohs Laboratory" approved via signature and date by the LD on 01/02/2023 failed to find evidence of the written duties and responsibilities for the CC, TS, GS, and TP as delegated by the LD. 3. The Inspector requested the duties and responsibilities of the CC, TS, GS, and TP from the MDM. The MDM confirmed the LD failed to specify in writing the duties and responsibilities of the CC, TS, GS, and TP and was unable to provide the requested information. The interview occurred on 10/02/2024 at 11:45 a.m. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - February 13, 2023

Survey Type: Standard

Survey Event ID: 2WIN11

Deficiency Tags: D6106 D6106

Summary:

Summary Statement of Deficiencies D6106 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(14) The laboratory director must ensure that an approved procedure manual is available to all personnel responsible for any aspect of the testing process. This STANDARD is not met as evidenced by: Based on review of the laboratory's policy and procedure manual and an interview with the Practice Manager (PM), the current Laboratory Director failed to ensure approved policies and procedures were available to all personnel responsible for any aspect of the testing process. This deficient practice had the potential to affect 10 patients tested under the subspecialty of Histopathology from 10/21/2022 through 01 /01/2023. Findings Include: 1. Review of the CMS116 submitted for a change of Laboratory Director revealed a new Laboratory Director as of 10/21/2022. 2. Review of the laboratory's policy and procedure manual titled, "Oakview Dermatology, Mohs Laboratory", found the current Laboratory Director signature dated 01/02/2023. 3 The inspector requested policies and procedures approved by the current Laboratory Director from the PM. The PM confirmed the policies and procedures were not approved and signed by the current Laboratory Director until 01/02/2023. The interview occurred on 02/13/2023 at 10:10 AM. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 1 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access